Company intelligence / Profile preview

Xiangxue Precision Medical Technology

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

TAEST16001 (NY-ESO-1 TCR-T therapy) has reached Phase 2 for soft tissue sarcoma and advanced clinical pipelines[1][8]. Early clinical studies in China have shown safety and efficacy signals for TCR-T cell therapy platforms[7].

Therapeutic areas: Oncology
Modalities: T cell receptor engineered T cell therapyCell therapyLentivirus (GMP-grade, for vector delivery)[1][2]
Industry: Biotech

Drug pipeline

10 assets

TAEST16001

9 more assets in the full pipeline.

Request access →

Partnerships

Axis Therapeutics Limited (joint preclinical program: TCRT ESO A2)[1]Xiangxue Pharmaceutical (collaborative relationship; possible shared R&D)[1][8]GE Healthcare (manufacturing platform/technology partnership)[5]

Beyond the preview

Go deeper on Xiangxue Precision Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiangxue Precision Medical Technology.

Explore the full profile